The Manufacturers Life Insurance Company Takes $928,000 Position in Omnicell, Inc. $OMCL

The Manufacturers Life Insurance Company purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 22,350 shares of the company’s stock, valued at approximately $928,000.

Several other institutional investors have also recently bought and sold shares of the stock. AQR Capital Management LLC boosted its position in Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after acquiring an additional 1,243 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after acquiring an additional 4,866 shares during the period. Jane Street Group LLC boosted its holdings in Omnicell by 201.5% in the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after acquiring an additional 109,382 shares during the last quarter. Finally, Creative Planning boosted its holdings in Omnicell by 16.7% in the second quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after acquiring an additional 1,347 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 1.3%

NASDAQ OMCL opened at $34.37 on Friday. The stock has a 50-day simple moving average of $39.34 and a 200 day simple moving average of $39.24. The company has a market capitalization of $1.56 billion, a PE ratio of 40.92, a P/E/G ratio of 0.86 and a beta of 0.97. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts forecast that Omnicell, Inc. will post 1.41 EPS for the current year.

Analysts Set New Price Targets

OMCL has been the subject of several recent research reports. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Omnicell has a consensus rating of “Moderate Buy” and an average price target of $57.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.